Parabilis Medicines, INC

Parabilis Medicines announced strong Q2 2026 results, highlighting advancements in zolucatetide trials, a major collaboration with Regeneron, and a robust cash position extending runway to 2030.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Parabilis Medicines, Inc. common stock on July 20, 2026.

SEC Form 4 filing reveals significant stock transactions by Guy Levy and associated Soleus entities on June 11, 2026.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 8.5% of Parabilis Medicines Inc.'s common stock as of June 30, 2026.